First-line treatment of advanced ovarian cancer: current research and perspectives

@article{Marchetti2010FirstlineTO,
  title={First-line treatment of advanced ovarian cancer: current research and perspectives},
  author={C. Marchetti and C. Pisano and G. Facchini and G. Bruni and Francesca Paola Magazzino and S. Losito and S. Pignata},
  journal={Expert Review of Anticancer Therapy},
  year={2010},
  volume={10},
  pages={47 - 60}
}
  • C. Marchetti, C. Pisano, +4 authors S. Pignata
  • Published 2010
  • Medicine
  • Expert Review of Anticancer Therapy
  • Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over recent decades, improvements have been made in treatment outcome in terms of response rate and survival. To date, intensive surgical staging and cytoreduction, followed by primary chemotherapy with the carboplatin–paclitaxel regimen, are considered the gold standard for the management of this disease. Nevertheless, despite good initial response to systemic therapy after optimal debulking surgery, the… CONTINUE READING
    61 Citations
    An overview of early investigational therapies for chemoresistant ovarian cancer
    • 15
    Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status.
    • 30
    Reducing excessive toxicity in ovarian cancer treatment: a personalized approach.
    • 3
    • Highly Influenced
    Examining the Selection Criteria of Neoadjuvant Chemotherapy Patients.
    Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.
    • 1
    Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses
    • 1
    Splenectomy during cytoreductive surgery in epithelial ovarian cancer
    • 6
    • PDF

    References

    SHOWING 1-10 OF 117 REFERENCES
    Pharmaceutical Management of Ovarian Cancer
    • 61
    New options for the treatment of advanced ovarian cancer.
    • 30
    Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
    • M. Bookman, M. Brady, +13 authors L. Roth
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2009
    • 578
    • PDF
    Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    • 701